Protagenic Therapeutics (PTIX) files NT 10-Q; 5-day extension

Protagenic Therapeutics (PTIX) filed a Form 12b-25, notifying a late filing of its Form 10-Q for the period ended September 30, 2025.

Rhea-AI Filing Summary

Protagenic Therapeutics (PTIX) filed a Form 12b-25, notifying a late filing of its Form 10-Q for the period ended September 30, 2025. The company states the report could not be completed without unreasonable effort or expense and expects to file within the five-day extension permitted by Rule 12b-25.

The notice is signed by CFO Alexander K. Arrow, MD, and lists a company contact for inquiries.

Insights

Regulatory Reporting Analyst

Standard NT 10-Q filing; brief delay with stated intent to file within five days. Watch for timely submission and any new disclosures in the 10-Q.

Protagenic Therapeutics, Inc. filed an NT 10-Q for the quarter ended September 30, 2025, stating it cannot file the Form 10-Q by the due date without unreasonable effort or expense. The company indicates it expects to file within the five-day extension permitted by Rule 12b-25.

This notification signals a timing delay rather than a disclosed operational or financial event. The form does not provide quantitative detail beyond the brief reason and timing. The section that asks about a significant change in results is present, but the filing text here does not show an indicated response.

Key items to watch: whether the Form 10-Q is filed within five calendar days of the original due date and any disclosures in that report regarding results, liquidity, internal controls, or subsequent events. The near-term marker is the anticipated filing within the Rule 12b-25 window, described as “within the next few days.”

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PTIX file?

PTIX filed a Form 12b-25 (NT 10-Q) to notify a late quarterly report.

Which period does the delayed 10-Q cover for PTIX?

The delayed Form 10-Q covers the period ended September 30, 2025.

When does PTIX expect to file the 10-Q?

PTIX expects to file the report within the five-day extension allowed under Rule 12b-25.

Why is PTIX’s 10-Q late?

The company says it could not complete the report without unreasonable effort or expense.

Who signed the notice for PTIX?

The notice was signed by Alexander K. Arrow, MD, Chief Financial Officer.

What is the contact number listed by PTIX?

The contact is Alexander Arrow at (213) 260-4342.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 05:04 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D  ☐Form N-SAR  ☐ Form N-CSR

For Period Ended: September 30, 2025

	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q
	☐	Transition Report on Form N-SAR

For the Transition Period Ended: ___________________________________________________________________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Protagenic Therapeutics, Inc.

Full Name of Registrant

Atrinsic, Inc.

Former Name if Applicable

149 Fifth Ave, Suite 500

Address of Principal Executive Office (Street and Number)

New York, NY 10010

City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

☒	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
☐	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III – NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Protagenic Therapeutics, Inc. (the “Company”) will not be able to file its Quarterly Report on Form 10-Q for the period ended September 30, 2025 by the prescribed due date without unreasonable effort or expense.

The Company expects to file the Form 10-Q within the next few days, and, in any case, within the five-day extension permitted by Rule 12b-25.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Alexander Arrow		213		260-4342
(Name)		(Area Code)		(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ☐ No ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Protagenic Therapeutics, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

	PROTAGENIC THERAPEUTICS, INC.
Date: November 14, 2025	By:	/s/ Alexander Arrow
	Name:	Alexander K. Arrow, MD
	Title:	Chief Financial Officer